title: [Drug eluting stents in 2005: have the initial expectations been met?].
abstract: Drug eluting stent is a new technology aimed to prevent the development of neointimal hyperplasia and restenosis following percutaneous coronary intervention. This review describes the direction for their use at the present time and the future of their utilization with the summary of the principals clinicals trials.
authors.affiliation: Fédération de cardiologie, centre hospitalier de Haguenau, 64, avenue du Professeur Leriche, 67504 Hagueneau, France. philippe.couppie@ch-haguenau.fr
authors.forename: P
authors.initials: P
authors.lastname: Couppié
authors.forename: F
authors.initials: F
authors.lastname: De Poli
authors.forename: C
authors.initials: C
authors.lastname: Thalouarn
authors.forename: F
authors.initials: F
authors.lastname: Fellinger
authors.forename: M
authors.initials: M
authors.lastname: Hanssen
authors.forename: M C
authors.initials: MC
authors.lastname: Dickelé
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation* / Q000379:methods; D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible; D003327:Coronary Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D016503:Drug Delivery Systems; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017239:Paclitaxel / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use; D015607:Stents / Q000639:trends; D050257:Tubulin Modulators / Q000627:therapeutic use
chemical_list: D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D050257:Tubulin Modulators; D017239:Paclitaxel; D020123:Sirolimus